Your browser doesn't support javascript.
loading
Antigen stabilizing hydrogels based on cyclodextrins and polyethylene glycol act as type-2 adjuvants with suppressed local irritation.
Hayashi, Tomoya; Nakagawa, Fumika; Ohno, Yoshitaka; Suzuki, Yusuke; Ishiki, Honatsu; Onodera, Risako; Higashi, Taishi; Shimamura, Yoshihisa; Itou, Hiroshi; Iwase, Yoichiro; Arima, Hidetoshi; Motoyama, Keiichi.
Afiliación
  • Hayashi T; Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT), Tokyo, Japan; Mock Up Vaccine, Center for
  • Nakagawa F; Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Ohno Y; Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; Program for Leading Graduate Schools 'Health Life Science: Interdisciplinary and Glocal Oriented (Higo) Program', Kumamoto University, Kumamoto, Japan; Cross-disciplinary Doctoral
  • Suzuki Y; Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Ishiki H; Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Onodera R; Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Higashi T; Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; Priority Organization for Innovation and Excellence, Kumamoto University, Kumamoto, Japan.
  • Shimamura Y; R&D Department, Pharmaceutical Solutions Division, Medical Care Solutions Company, Terumo Corporation, Kanagawa, Japan.
  • Itou H; R&D Department, Pharmaceutical Solutions Division, Medical Care Solutions Company, Terumo Corporation, Kanagawa, Japan.
  • Iwase Y; R&D Department, Pharmaceutical Solutions Division, Medical Care Solutions Company, Terumo Corporation, Kanagawa, Japan.
  • Arima H; Laboratory of Evidence-based Pharmacotherapy, School of Pharmacy, Daiichi University of Pharmacy, Fukuoka, Japan. Electronic address: h-arima@daiichi-cps.ac.jp.
  • Motoyama K; Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan. Electronic address: motoyama@kumamoto-u.ac.jp.
Eur J Pharm Biopharm ; 181: 113-121, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36372270
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas / Ciclodextrinas Idioma: En Revista: Eur J Pharm Biopharm Asunto de la revista: FARMACIA / FARMACOLOGIA Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas / Ciclodextrinas Idioma: En Revista: Eur J Pharm Biopharm Asunto de la revista: FARMACIA / FARMACOLOGIA Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos